36-month results from first-in-human study with shape-changing IOL

Atia Vision announced that the 36-month, first-in-human results have been presented for its OmniVu Lens System, described as a modular shape-changing IOL. The study included 19 cataract patients (29 eyes; 10 cases were binocular and 9 monocular). In a press release, the company reported stable refractive outcomes (MRSE stable through 36-months of follow-up within 0.5 D of target) and strong binocular visual acuity with mean binocular uncorrected distance visual acuity at –0.11 logMAR (20/16) and mean best-corrected distance visual acuity at –0.17 logMAR (20/12). “Mean binocular uncorrected intermediate visual acuity was –0.05 logMAR (20/20) and mean binocular uncorrected near visual acuity was 0.06 logMAR (20/25, J1),” the company reported. All eyes in the study had a favorable safety profile, with no lens exchanges or refractive enhancements; there was one YAG required. Contrast sensitivity was like that of monocular mesopic performance.

Back to top

New data for recently approved EDOF IOL

Johnson & Johnson announced new data for its TECNIS PureSee IOL, which recently received FDA approval. Data for this EDOF IOL, according to the company’s press release, confirms its ability to provide high contrast sensitivity and visual acuity across all distances with few visual disturbances. The U.S. prospective, randomized trial showed “high-quality distance visual acuity, significantly improved intermediate vision vs. monofocal control TECNIS 1-pc IOL, with some near vision gained while maintaining contrast sensitivity comparable to an aspheric monofocal IOL and low levels of visual symptoms,” according to the company. Another study with real-world visual outcomes from Europe and Asia-Pacific showed “excellent clinical outcomes, low bothersome visual symptoms, and high patient satisfaction with limited spectacle use,” as well as a high tolerance to postop refractive errors.

Back to top

Company completes first-in-human robotic cataract surgery

ForSight Robotics completed its first-in-human cataract surgery with its JASPER Platform, with the procedure performed by Alexey Rapoport, MD, and Robert Ang, MD, serving as the principal investigator. This procedure was conducted from start to finish without general anesthesia, which the company reported “[aligns] with the current standard practice of modern cataract procedures.” The technology will now advance in clinical validation and toward regulatory submissions.

Back to top

Phase 2 study approved for secondary IOL intended for low-vision patients

OnPoint Vision received approval to conduct a Phase 2 study of its pivotal clinical trial for the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG), which is intended for secondary implantation in the capsular bag with an existing 6-mm acrylic posterior chamber IOL. This investigational lens is designed for unilateral implantation in patients with low vision due to inactive AMD at least 6 months after their original cataract surgery. It has a plano power with a central +10 D 1.8-mm zone that’s designed to magnify near images. The company, in its press release, stated that the IOPCL was originally created to correct residual refractive error after cataract surgery, but the lens platform has been more recently under investigation for “a variety of pseudophakic refractive applications.”

Back to top

Investigational device measures real-time intraoperative aqueous outflow

Sean Ianchulev, MD, at the ASCRS Annual Meeting in his Charles D. Kelman Innovator’s Lecture, unveiled a number of new technologies in the pipeline that he’s had a hand in developing (read more here). One of these was miDOC (micro-interventional dynamic outflow curve), which is being developed and investigated at New York Eye and Ear Infirmary (NYEE) of Mount Sinai. The technology, according to a press release from NYEE, which states that it is the only center in the U.S. to use the technology and conduct a first-in-human study, is designed to provide intraoperative measurement of outflow and pressure in the eye. The intent of the miDOC technology would be to measure the effect of outflow interventions in real time. NYEE, in its press release, stated that it began using the technology in 2025 and has completed 20 cases, using it to measure pressure, flow, outflow facility, and ocular rigidity/compliance. miDOC is currently undergoing further refinement and will pursue regulatory approval in the future, according to NYEE.

Back to top

FDA expands dosing on label for faricimab

Genentech announced that it received a label update for Vabysmo (faricimab-svoa) from the FDA, allowing treatment of macular edema due to retinal vein occlusion to beyond 6 months. This update, according to company representatives in a press release, will reduce treatment switches for patients who are still benefitting from Vabysmo.

Back to top

Company news

• Cassini Technologies and Leica Microsystems are collaborating to advance the Cassini Guidance System.
• Halma, the parent company of MicroSurgical Technology (MST), has acquired Surgistar, which is a U.S.-based manufacturer of ophthalmic instruments and devices.

Back to top

ASCRS news and events

• ASCRS Annual Meeting: Thank you to all who attended the 2026 ASCRS Annual Meeting in Washington, D.C. ASCRS is already planning for next year—book your 2027 hotel in San Diego.
• EyeWorld Onsite: Did you miss content from the 2026 ASCRS Annual Meeting? Read live coverage and see photos from key symposia and events in EyeWorld Onsite.
• ASCRS Live!: This educational dinner series is heading to several cities across the U.S. in 2026. Registration is open for the next event in Omaha, Nebraska, on June 11.
• ASCRS Online Education: The ASCRS CME Education Catalog offers a wealth of both CME and non-CME content for ASCRS members. Check out what your colleagues have been watching lately.

Back to top

Research highlights

• Two dispersive ophthalmic viscosurgical devices were evaluated in a multicenter study conducted in Europe. The prospective, randomized, masked, post-market study compared investigational Z-HYALCOAT (sodium hyaluronate 3%, Zeiss) to HEALON EndoCoat (sodium hyaluronate 3%, Johnson & Johnson), which served as the control. The study included 242 participants, 123 treated with the investigational OVD and 119 with the control. Thirteen eyes and 19 eyes from the investigational and control groups, respectively, had an IOP of 30 mm Hg or greater at 8 hours after OVD use. Three months postop, there were no significant, relevant differences between the two groups. Endothelial cell loss was similar, and according to the investigations “surgeon-reported OVD functionality was generally favorable and comparable for both devices.” The research was published in the Journal of Cataract & Refractive Surgery.
• The pre-, intra-, and postop risk factors for developing an IOL dislocation that required surgical intervention were identified in a retrospective, multicenter clinical database center based on 12 years of data from 8 U.K. centers. More than 176,000 eyes had phaco cataract surgery and of these, 145 (0.08%) experienced an IOL dislocation postop. The risk factors included the following: being between 18–40 years old and between 40–60 years old, being male, pseudoexfoliation, zonular dialysis, posterior capsule rupture, combined phaco and a pars plana vitrectomy, and having a YAG capsulotomy. This information, according to study authors, is clinically useful for surgeons when it comes to risk stratification and surgical planning. The research is published in the journal Clinical Ophthalmology.

Back to top

Product news

• REFRESH OPTIVE MEGA-3 Multi-Dose Preservative-Free (AbbVie) is now available in multidose bottles, joining the single-use vials in the REFRESH Portfolio.
• The FDA granted 510(k) approval to the Pentacam Cornea OCT (Oculus).
• Bausch + Lomb received 510(k) clearance from the FDA for its Bi-Blade+ advanced dual-port vitrectomy cutter, and for Adaptive Fluidics, its update on the Stellaris Elite Vision Enhancement System.

Back to top

---